| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CMDC.202000007 |
| P698 | PubMed publication ID | 32181984 |
| P50 | author | Annissa J Huhn | Q58579056 |
| Jonathan E Wilson | Q90388888 | ||
| P2093 | author name string | Florence Poy | |
| James E Audia | |||
| Chirag Patel | |||
| Archana Bommi-Reddy | |||
| Julian Levell | |||
| Robert Sims | |||
| Nico Cantone | |||
| Gaurav Patel | |||
| Richard Cummings | |||
| Annissa J Huhn | |||
| Francois Brucelle | |||
| Valerie Vivat | |||
| P2860 | cites work | Interpreting steep dose-response curves in early inhibitor discovery | Q46152094 |
| Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases | Q49949196 | ||
| Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome | Q63383561 | ||
| Kinetic mechanism of human histone acetyltransferase P/CAF | Q73015506 | ||
| Make the right measurement: Discovery of an allosteric inhibition site for p300-HAT | Q90932611 | ||
| A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A | Q24336667 | ||
| A direct link between core histone acetylation and transcriptionally active chromatin | Q24563586 | ||
| ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS | Q24629431 | ||
| KATs in cancer: functions and therapies | Q26859355 | ||
| Protein lysine acetylation by p300/CBP | Q27021749 | ||
| Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits | Q27314989 | ||
| The structural basis of protein acetylation by the p300/CBP transcriptional coactivator | Q27649849 | ||
| The transcriptional coactivators p300 and CBP are histone acetyltransferases | Q27860843 | ||
| Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction | Q27860958 | ||
| The CBP co-activator is a histone acetyltransferase | Q28131758 | ||
| Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor | Q33599508 | ||
| Native MS: an 'ESI' way to support structure- and fragment-based drug discovery | Q33852381 | ||
| Histone acetyltransferases are crucial regulators in NF-κB mediated inflammation. | Q33866592 | ||
| HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. | Q33908350 | ||
| The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis | Q34636005 | ||
| Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders. | Q38085375 | ||
| A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach. | Q38904705 | ||
| Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer | Q39018415 | ||
| Native Mass Spectrometry: What is in the Name? | Q39578058 | ||
| Regulation of the p300 HAT domain via a novel activation loop. | Q42458138 | ||
| Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. | Q44963439 | ||
| P921 | main subject | drug discovery | Q1418791 |
| P577 | publication date | 2020-03-17 | |
| P1433 | published in | ChemMedChem | Q2962252 |
| P1476 | title | Early Drug-Discovery Efforts towards the Identification of EP300/CBP Histone Acetyltransferase (HAT) Inhibitors |
| Q99418746 | Targeting the epigenetic regulation of antitumour immunity | cites work | P2860 |
Search more.